GROWTH EQUITY OPPORTUNITIES 17, LLC -- VISTAGEN--SCH 13D

Company

Vistagen Therapeutics, Inc.

Filed

January 4, 2021

Accession Number

0001072613-21-000001

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →